NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
Clinical Trials
18 trialsNCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00573131 2022-06-22
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT00003487 2021-05-14
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
Burzynski Research Institute
Phase 2 Terminated
NCT00006472 2020-08-18
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT03122548 2019-04-04
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Aduro Biotech, Inc.
Phase 2 Terminated
NCT00493025 2018-12-06
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03223662 2018-10-30
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02234180 2018-10-17
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02392377 2018-02-13
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT02016534 2017-07-02
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
Amgen
Phase 2 Terminated
NCT00268437 2016-07-06
Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01870791 2016-05-26
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
University Hospitals, Leicester
Phase 2 Terminated
NCT00109850 2015-11-18
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT00258297 2013-10-16
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
University of Rochester
Phase 2 Terminated
NCT00098527 2013-07-02
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00061958 2013-01-23
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00004897 2012-06-12
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Northwestern University
Phase 2 Terminated